Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The submission is ...

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Bayer BAYRY announced the submission of a supplemental new drug application (sNDA) to the FDA for darolutamide. The sNDA is ...

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery ...

A new study sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care.

Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...

German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday the submission of a supplemental new drug ...

A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes ...

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without ...

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

Darolutamide plus androgen deprivation therapy (ADT), without docetaxel, significantly prolonged radiographic progression-free survival compared with placebo plus ADT in patients with metastatic ...